Ligand Pharmaceuticals Incorporated ( Nachrichten ) (NASDAQ:LGND) today announced positive results from a Phase I clinical trial with LGD-4665 in a poster titled “ Single and Multiple Oral Doses of LGD-4665, a Small Molecule Thrombopoeitin Receptor Agonist, Increase Platelet Counts in Healthy Male Subjects, “? at the American Society of Hematology (ASH) 49 th Annual Meeting, being held at the ...
More...
More...